Non-Hodgkin’s Lymphoma (NHL) Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Non-Hodgkin’s Lymphoma Information Center has current, evidence-based information for you. Get the facts about non-Hodgkin’s lymphoma early detection, treatment, and survivorship, and stay up to date with ongoing non-Hodgkin’s lymphoma research that could impact your treatment decisions through our daily cancer news. Check out our new blog from Jamie Reno on The Lymphoma Drug that Saved My Life here.
You are not alone—The CancerConnect Non-Hodgkin’s Lymphoma Community is the leading Social Media Application for Non-Hodgkin’s Lymphoma patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
The FDA has approved Imbruvica for the treatment of patients with mantle cell lymphoma. Pidilizumab Plus Rituxan Produces High Response Rate in Relapsed Follicular Lymphoma
Treatment with the monoclonal antibody pidilizumab plus Rituxan produced a high response rate in patients with relapsed follicular lymphoma. Link Between Allergies and Blood Cancers in Women
Researchers hare found a link between airborne allergies and the risk of blood cancers in women.
Cancer and its treatment can come with a variety of complications, some more serious... What is Radioimmunotherapy (RIT) Treatment of NHL?
Radioimmunotherapy (RIT) is a type of targeted therapy that delivers radiation directly... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse...
Non-Hodgkin’s Lymphoma Management
Sean Swarner is a master of setting a goal and achieving it. So when he... Jack & Jill Late Stage Cancer Foundation
Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the... Moving Bodies, Changing Lives
Moving On Aerobics helps women regain joy of movement and physical fitness after...
Non-Hodgkin’s Lymphoma Clinical Trials
COGANHL01P1 – A Pilot study to determine the Toxicity of the addition of Rituximab to the Inducation and Consolidation phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-cell leukemia/lymphoma treated with LMB/FAB Therapy
SeaGenMarinerStudy – A Randomized Phase IIb Placebo-controlled study of R-ICE Chemotherapy (RItuximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for second-line treatment of patients with diffuse large B-cell lymphoma (DLBCL)
114-NH-301 – Phase III, Randomized, Double-blind Study of Glaiximab in combination with Rituximab compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non-Hodgkin’s Lymphoma.